Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 4/20 | 0.44 |
| ▸ | SCN1A | P35498 | 2/20 | 0.42 |
| ▸ | SCN8A | Q9UQD0 | 2/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | CCR3 | P51677 | 1/20 | 0.41 |
| ▸ | HTR1D | P28221 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8097670 | 0.92 | CCR3 (0.43) | MEN1KMT2AMCHR1ENPP2CCR3 | |
| SCHEMBL5526683 | 0.90 | SCN1A (0.50) | MCHR1SCN1ASCN8A | |
| SCHEMBL8100160 | 0.89 | HTR1A (0.45) | ACHEMEN1KMT2ASCN1ASCN8A | |
| SCHEMBL8102253 | 0.88 | HTR1A (0.47) | MCHR1SCN1ASCN8AHTR1D | |
| SCHEMBL4246391 | 0.87 | SCN1A (0.42) | ENPP2SCN1ASCN8AHTR1D | |
| SCHEMBL8085163 | 0.86 | SCN1A (0.47) | MCHR1SCN1ASCN8A | |
| SCHEMBL4245768 | 0.86 | NPC1 (0.48) | MEN1KMT2ASCN1ASCN8A | |
| SCHEMBL8095680 | 0.86 | PDE4B (0.46) | ACHEMEN1KMT2ASCN1ASCN8A | |
| SCHEMBL8095861 | 0.86 | KCNH2 (0.41) | SCN1ASCN8AHTR1D | |
| SCHEMBL8108269 | 0.85 | RAB9A (0.47) | MEN1KMT2ASCN1ASCN8A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023773-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-01-22 | — | — | US | disclosed |
| US-20090023773-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-01-22 | — | — | US | disclosed |
| WO-2009000085-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES USEFUL AS MODULATORS OF GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023773-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | TRPV1, TRPV2, TRPA1 | ACHE 274/4885MEN1 4478/4885KMT2A 3931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.